Fennec Pharmaceuticals INC Form 4 insider transactions

Fennec Pharmaceuticals CFO Robert Andrade acquired 1,703 common shares through the release of restricted stock units.

Chief Medical Officer Pierre Sayad acquired 168 common shares of Fennec Pharmaceuticals through the release of restricted stock units.

Chief Medical Officer Pierre Sayad reported the vesting of performance units and the receipt of new stock options.

Fennec Pharmaceuticals CFO Robert Andrade exercised restricted stock units and received a new grant of 120,000 stock options.

Chief Commercial Officer Terry Evans acquired common shares through PSU settlement and received a new stock option grant.

Fennec Pharmaceuticals' CFO, Robert Andrade, exercised stock options, acquiring 13,072 common shares at $5.10 per share.

Fennec Pharmaceuticals' Chief Strategy Officer, Christiana Marie Cioffi, exercised 4,700 stock options at $4.23 per share.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,191 common shares through the release of restricted stock.

Fennec Pharmaceuticals director Rosty Raykov exercised stock options and sold shares to cover tax obligations, alongside the release of restricted stock, all under a pre-arranged 10b5-1 plan.

Fennec Pharmaceuticals CEO Jeffrey S. Hackman acquired 13,710 common shares through the settlement of vested Performance Share Units.

Fennec Pharmaceuticals' CFO, Robert Andrade, increased his direct beneficial ownership through option exercises and PSU settlements.

Fennec Pharmaceuticals Director Rosty Raykov executed a pre-planned transaction, exercising stock options and selling a portion of the acquired shares to cover tax obligations.

Fennec Pharmaceuticals director Rosty Raykov reported the acquisition of 5,208 common shares through the release of restricted stock.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,558 common shares through the release of restricted stock.

Fennec Pharmaceuticals' CFO, Robert Andrade, exercised 10,000 stock options at $2.45 per share, increasing his direct ownership of common shares.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, exercised options to acquire 10,000 common shares at $2.45 per share.

Fennec Pharmaceuticals CFO Robert Andrade acquired 14,184 common shares by exercising stock options at $2.45 per share.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, reported the acquisition of 1,382 common shares through a restricted stock release.

Fennec Pharmaceuticals Director Rosty Raykov reported the acquisition of shares from restricted stock and option exercise, alongside a sale to cover tax obligations, all under a pre-arranged 10b5-1 plan.

Southpoint Capital Advisors LP, a 10% owner, reported the sale of 1,000,000 shares of Fennec Pharmaceuticals Inc. common stock for $7.50 per share.

Fennec Pharmaceuticals director Rosty Raykov sold 10,000 common shares for $7.54 each, totaling $75,400, as part of a pre-arranged 10b5-1 trading plan.

Fennec Pharmaceuticals' CFO, Robert Andrade, reported the acquisition of 2,430 common shares through the release of previously restricted stock.

Fennec Pharmaceuticals Director Rosty Raykov acquired 5,208 common shares through the release of restricted stock.

Southpoint Capital Advisors, a 10% owner and director, reported the sale of 19,341 Fennec Pharmaceuticals common shares at a weighted average price of $8.7921 per share.

Southpoint Capital Advisors, a 10% owner and director, reported sales of Fennec Pharmaceuticals common stock totaling 246,018 shares in mid-November 2025.

Fennec Pharmaceuticals Director Rosty Raykov sold 10,000 common shares for $8.10 each, reducing his direct beneficial ownership to 82,318 shares.

Fennec Pharmaceuticals Director Rosty Raykov acquired 5,208 common shares through the release of restricted stock.

Fennec Pharmaceuticals' CFO, Robert Andrade, acquired 2,430 common shares through the release of restricted stock.

Fennec Pharmaceuticals Director Chris Rallis executed pre-planned transactions, exercising stock options and selling a portion of the acquired shares to cover tax obligations.

Southpoint Capital Advisors, a 10% owner and director, reported selling over 67,000 shares of Fennec Pharmaceuticals common stock in early October 2025.